| Table3. Baseline demographics and disease characteristics of patients with VETC+ and VETC- after PSM. | ||||
| Characteristic | Overall N = 36 |
VETC- N = 20 |
VETC+ N = 16 |
p-value1 |
|---|---|---|---|---|
| Age, Mean ± SD | 54.83 ± 11.87 | 55.18 ± 13.45 | 54.40 ± 9.95 | 0.844 |
| Gender, n (%) | 0.613 | |||
| Female | 4.00 (11.11) | 3.00 (15.00) | 1.00 (6.25) | |
| Male | 32.00 (88.89) | 17.00 (85.00) | 15.00 (93.75) | |
| HBV infection, n (%) | 27.00 (75.00) | 14.00 (70.00) | 13.00 (81.25) | 0.700 |
| ECOG PS, n (%) | 0.196 | |||
| 0 | 29.00 (80.56) | 15.00 (75.00) | 14.00 (87.50) | |
| 1 | 6.00 (16.67) | 5.00 (25.00) | 1.00 (6.25) | |
| 3 | 1.00 (2.78) | 0.00 (0.00) | 1.00 (6.25) | |
| Tumor Num, n (%) | >0.999 | |||
| <3 | 10.00 (27.78) | 6.00 (30.00) | 4.00 (25.00) | |
| ≥3 | 26.00 (72.22) | 14.00 (70.00) | 12.00 (75.00) | |
| Tumor Size, n (%) | >0.999 | |||
| <5 | 31.00 (86.11) | 17.00 (85.00) | 14.00 (87.50) | |
| ≥5 | 5.00 (13.89) | 3.00 (15.00) | 2.00 (12.50) | |
| Lymphatic metastasis, n (%) | 16.00 (44.44) | 11.00 (55.00) | 5.00 (31.25) | 0.154 |
| Distant metastasis, n (%) | 18.00 (50.00) | 10.00 (50.00) | 8.00 (50.00) | >0.999 |
| Presentation of PVTT, n (%) | 7.00 (19.44) | 5.00 (25.00) | 2.00 (12.50) | 0.426 |
| Edmondson-Steiner Grade, n (%) | 0.782 | |||
| 1 | 2.00 (5.56) | 1.00 (5.00) | 1.00 (6.25) | |
| 2 | 31.00 (86.11) | 18.00 (90.00) | 13.00 (81.25) | |
| 3 | 3.00 (8.33) | 1.00 (5.00) | 2.00 (12.50) | |
| MVI, n (%) | 24.00 (66.67) | 12.00 (60.00) | 12.00 (75.00) | 0.343 |
| BCLC stage, n (%) | >0.999 | |||
| 0/A | 7.00 (19.44) | 4.00 (20.00) | 3.00 (18.75) | |
| B/C | 29.00 (80.56) | 16.00 (80.00) | 13.00 (81.25) | |
| TNM stage, n (%) | 0.159 | |||
| Ⅰ/Ⅱ | 11.00 (30.56) | 4.00 (20.00) | 7.00 (43.75) | |
| Ⅲ/Ⅳ | 25.00 (69.44) | 16.00 (80.00) | 9.00 (56.25) | |
| AFP, n (%) | 0.709 | |||
| <400 | 28.00 (77.78) | 15.00 (75.00) | 13.00 (81.25) | |
| ≥400 | 8.00 (22.22) | 5.00 (25.00) | 3.00 (18.75) | |
| PIVKA-Ⅱ, n (%) | 0.650 | |||
| <100 | 15.00 (41.67) | 9.00 (45.00) | 6.00 (37.50) | |
| ≥100 | 21.00 (58.33) | 11.00 (55.00) | 10.00 (62.50) | |
| CRP, Median (Q1, Q3) | 4.25 (1.42, 18.15) | 2.29 (1.41, 17.00) | 9.09 (1.79, 27.75) | 0.340 |
| TBIL, Mean ± SD | 14.64 ± 5.93 | 14.56 ± 6.69 | 14.74 ± 5.03 | 0.924 |
| ALB, Median (Q1, Q3) | 42.20 (36.65, 45.10) | 42.45 (36.50, 45.35) | 41.50 (37.35, 44.80) | 0.962 |
| ALBI, n (%) | 0.587 | |||
| 1 | 23.00 (63.89) | 12.00 (60.00) | 11.00 (68.75) | |
| 2 | 13.00 (36.11) | 8.00 (40.00) | 5.00 (31.25) | |
| Child-Pugh, n (%) | >0.999 | |||
| 1 | 35.00 (97.22) | 19.00 (95.00) | 16.00 (100.00) | |
| 2 | 1.00 (2.78) | 1.00 (5.00) | 0.00 (0.00) | |
| 1 Welch Two Sample t-test; Fisher’s exact test; Pearson’s Chi-squared test; Kruskal-Wallis rank sum test | ||||